Marrone Bio Innovations Raises $25.4 Million Series C Financing

Marrone Bio Innovations, Inc. (MBI) is pleased to announce the closing of a $25.4 million private round of financing with three new investors and re-investment of existing investors.

New investors investing in this Series C preferred financing are Syngenta Ventures, Mitsui Global Investment, and a family investment trust. Existing investors include Stuart Mill Venture Partners, Contrarian Group, Saffron Hill Ventures, One Earth Capital, Clean Pacific Ventures, and Calvert Equity Portfolio, in addition to several individuals. Contrarian Group’s CFO, Tim Fogarty has joined the Board.

The financing is being used for expanding global sales of Regalia® Biofungicide, launch of Zequanox™ and other pipeline products upon EPA approval and for development of new nematicides, herbicides, and fungicides from the discovery screen.

"We are very pleased to receive investment from new investors and to have the support of our existing investors. Their size and prominence as well as the amount funded recognize our rapid progress in the marketplace, unsurpassed product pipeline, and unique discovery capability,” said Dr. Pam Marrone, MBI’s Founder and CEO.